These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 7658292)

  • 1. Benefit-cost analysis of drug abuse prevention programs: a macroscopic approach.
    Kim S; Coletti SD; Crutchfield CC; Williams C; Hepler N
    J Drug Educ; 1995; 25(2):111-27. PubMed ID: 7658292
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Organizational and client determinants of cost in outpatient substance abuse treatment.
    Beaston-Blaakman A; Shepard D; Horgan C; Ritter G
    J Ment Health Policy Econ; 2007 Mar; 10(1):3-13. PubMed ID: 17417043
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Estimating the economic cost of substance abuse treatment.
    French MT; McGeary KA
    Health Econ; 1997; 6(5):539-44. PubMed ID: 9353658
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Applying benefit-cost analysis to substance use prevention programs.
    Plotnick RD
    Int J Addict; 1994 Feb; 29(3):339-59. PubMed ID: 8188432
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Substance abuse treatment services: an introduction.
    Lowman C
    J Ment Health Adm; 1992; 19(1):1-4. PubMed ID: 10171033
    [No Abstract]   [Full Text] [Related]  

  • 6. Effectiveness and cost-effectiveness of four treatment modalities for substance disorders: a propensity score analysis.
    Mojtabai R; Zivin JG
    Health Serv Res; 2003 Feb; 38(1 Pt 1):233-59. PubMed ID: 12650390
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Insights from a national survey into why substance abuse treatment units add prevention and outreach services.
    Wells R; Lemak CH; D'Aunno TA
    Subst Abuse Treat Prev Policy; 2006 Aug; 1():21. PubMed ID: 16887037
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The cost and cost-effectiveness of an enhanced intervention for people with substance abuse problems at risk for HIV.
    Zarkin GA; Lindrooth RC; Demiralp B; Wechsberg W
    Health Serv Res; 2001 Jun; 36(2):335-55. PubMed ID: 11409816
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improving cost-effectiveness in a substance abuse treatment program.
    Francis E; Hughes P; Schinka J
    Psychiatr Serv; 1999 May; 50(5):633-5. PubMed ID: 10332897
    [No Abstract]   [Full Text] [Related]  

  • 10. Benefit-cost analysis of addiction treatment: methodological guidelines and empirical application using the DATCAP and ASI.
    French MT; Salomé HJ; Sindelar JL; McLellan AT
    Health Serv Res; 2002 Apr; 37(2):433-55. PubMed ID: 12036002
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A profile of the substance abuse treatment industry: organization, costs, and treatment completion.
    Woodward AM; Raskin IE; Blacklow B
    Subst Use Misuse; 2008; 43(5):647-79. PubMed ID: 18393082
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug treatment takes a hit. As substance abuse has surged among teens, coverage for care has been curtailed.
    Gardner J
    Mod Healthc; 1996 Oct; 26(43):66, 68, 70-2. PubMed ID: 10172795
    [No Abstract]   [Full Text] [Related]  

  • 13. Costs and benefits of combining probation and substance abuse treatment.
    Alemi F; Taxman F; Baghi H; Vang J; Thanner M; Doyon V
    J Ment Health Policy Econ; 2006 Jun; 9(2):57-70. PubMed ID: 17007484
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of family-based substance abuse treatment.
    Morgan TB; Crane DR
    J Marital Fam Ther; 2010 Oct; 36(4):486-98. PubMed ID: 21039660
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Utilization and costs of substance abuse services within The HMO Group.
    Levin BL
    HMO Pract; 1993 Mar; 7(1):28-34. PubMed ID: 10171407
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevention validation and accounting platform: a framework for establishing accountability and performance measures of substance abuse prevention programs.
    Kim S; McLeod JH; Williams C; Hepler N
    J Drug Educ; 2000; 30(1):1-143. PubMed ID: 10893910
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Benefits and costs associated with mutual-help community-based recovery homes: The Oxford House model.
    Lo Sasso AT; Byro E; Jason LA; Ferrari JR; Olson B
    Eval Program Plann; 2012 Feb; 35(1):47-53. PubMed ID: 22054524
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Guidelines and challenges for estimating the economic costs and benefits of adolescent substance abuse treatments.
    Zavala SK; French MT; Henderson CE; Alberga L; Rowe C; Liddle HA
    J Subst Abuse Treat; 2005 Oct; 29(3):191-205. PubMed ID: 16183468
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness and benefit-cost of peer-based workplace substance abuse prevention coupled with random testing.
    Miller TR; Zaloshnja E; Spicer RS
    Accid Anal Prev; 2007 May; 39(3):565-73. PubMed ID: 17125723
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Estimating the dollar value of health outcomes from drug-abuse interventions.
    French MT; Mauskopf JA; Teague JL; Roland EJ
    Med Care; 1996 Sep; 34(9):890-910. PubMed ID: 8792779
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.